Alligator Bioscience AB AI Stock Analysis
Want to see SE:ATORX full AI Analyst Report?
Alligator Bioscience AB (ATORX) AI Stock Analysis
Alligator Bioscience AB
(Nasdaq OMX AB:ATORX)
Alligator Bioscience scores near the bottom of the range. The dominant factor is its financial profile: effectively no revenue, losses at every level, a near-exhausted equity base, debt that exceeds equity, and annual cash burn larger than total assets — leaving the company dependent on fresh capital or a partnership to continue operating. Technicals reinforce the caution, with the share trading below all major moving averages, negative MACD and weak momentum indicators. Valuation provides no cushion, as the negative P/E reflects persistent losses and there is no dividend. The modest offset is management's cost discipline, which has more than halved operating losses and cash burn since 2024 and restored equity to positive territory, but this is not enough to change a high-risk profile driven by clinical and financing outcomes.
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 30.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 37.74M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.94
- Revenue Growth
- -99.33%
- EPS Growth
- 64.90%
- Country
- Sweden
- Employees
- 11
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Alligator Bioscience AB Business Overview & Revenue Model
Company Description
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its dru...
How the Company Makes Money
Alligator Bioscience primarily generates or seeks to generate revenue through: (1) out-licensing and partnering its drug candidates and underlying antibody discovery/optimization capabilities to larger pharmaceutical or biotech companies in exchange...
Alligator Bioscience AB Financial Statement Overview
Summary
Financials are very weak, even by clinical-stage biotech standards. Revenue has effectively disappeared (SEK 0.3 million TTM versus SEK 57.8 million in 2024), gross profit is negative SEK 23.4 million, operating income is negative SEK 96.9 million, and the net loss is SEK 82.1 million. The balance sheet is fragile: equity has collapsed from SEK 282.3 million in 2021 to just SEK 23.2 million after dipping into deficit in 2024, while debt of SEK 27.8 million exceeds equity for a stretched ~9x debt-to-equity position. Cash flow is the biggest concern, with TTM operating and free cash flow both at negative SEK 97.3 million — more than the entire SEK 89.4 million asset base — implying heavy reliance on new equity raises or partnering income and material dilution/going-concern risk. The one genuine positive is cost discipline: operating losses and cash burn have been cut by more than half since 2024 and equity has been restored to positive territory.
Income Statement
8Very NegativeBalance Sheet
11Very NegativeCash Flow
7Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 283.00K | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -38.25M | -54.82M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -95.92M | -121.98M | -165.47M | -237.61M | -180.99M | -130.36M |
| Net Income | -82.10M | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | ||||||
| Total Assets | 89.41M | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 41.25M | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 27.78M | 43.15M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 66.23M | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 23.17M | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | ||||||
| Free Cash Flow | -97.31M | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -97.31M | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 0 | 2.21M | 0 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 113.70M | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 31.41 is Neutral, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:BINV49Neutral
SE:IMMU48Neutral
SE:ELIC47Neutral
SE:ONCO44Neutral
SE:ATORX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 369.63M | 1.93 | 63.09% | ― | ― | ― | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 49Neutral | SEK 193.46M | -0.40 | -128.54% | ― | -83.67% | -50.29% | |
| 48Neutral | SEK 240.41M | -2.12 | -19.14% | ― | ― | 13.06% | |
| 47Neutral | SEK 164.51M | -6.97 | -56.09% | ― | ― | 14.10% | |
| 44Neutral | SEK 747.11M | -2.75 | ― | ― | 65.37% | 43.28% | |
| 39Underperform | SEK 30.69M | -0.01 | -439.98% | ― | -99.33% | 64.90% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ATORX | Alligator Bioscience AB | 0.01 | -0.19 | -94.97% | |
| SE:BINV | BioInvent International AB | 2.94 | -28.31 | -90.59% | |
| SE:ONCO | Oncopeptides AB | 1.73 | -3.10 | -64.14% | |
| SE:ELIC | Elicera Therapeutics AB | 2.46 | -2.66 | -51.90% | |
| SE:IMMU | Immunicum AB | 3.79 | -1.51 | -28.49% | |
| SE:CANTA | Cantargia AB | 1.31 | -1.86 | -58.64% |
Alligator Bioscience AB Corporate Events
Alligator Bioscience Appoints Nomination Committee for 2027 AGM
Alligator Bioscience is a biotechnology company historically focused on tumor-directed immuno-oncology. Following a strategic refocus, it is prioritizing its economic interest in HLX22, an anti-HER2 monoclonal antibody developed by Shanghai Henlius,...
Alligator Bioscience Sells Mitazalimab Rights to Biossil in Strategic Refocus on HLX22
Alligator Bioscience has agreed to sell all global rights and assets related to its CD40 agonist antibody mitazalimab to Biossil Inc., including patents, clinical and regulatory data, manufacturing materials, drug inventory, and all future developmen...
Alligator Bioscience Boosts Share Count After Rights Issue
Alligator Bioscience AB has increased its number of shares and votes following a rights issue of units approved by the board in July 2026 and confirmed by an extraordinary general meeting in August 2026. As of 30 October 2026, the company’s total num...
Alligator Bioscience Plans 1-for-1,000 Reverse Share Split and Warrant Term Adjustments
Alligator Bioscience AB plans to seek shareholder approval at an Extraordinary General Meeting on 27 November 2026 for a 1-for-1,000 reverse split of its ordinary shares, consolidating the total number from about 3.57 billion to roughly 3.57 million...
Alligator Bioscience Calls Extraordinary Meeting to Restructure Share Capital and Board
Alligator Bioscience AB has called an extraordinary general meeting for 27 November 2026 in Lund, Sweden, inviting shareholders to vote on a series of corporate actions. The meeting will address share capital restructuring measures, board composition...
Alligator Bioscience Refocuses Strategy on HLX22 and Bolsters Finances
Alligator Bioscience has undertaken a strategic refocus in the third quarter of 2026, discontinuing independent development of its lead asset mitazalimab and concentrating on its financial interest in HLX22, which is advancing through global Phase 3...
Alligator Bioscience to Present Q3 HER2-Focused Interim Report on 22 October
Alligator Bioscience will publish its interim report for the July–September 2026 period, focused on its HER2-targeting activities, on 22 October 2026 at 8:00 a.m. CEST. The company will the same day host an English-language webinar and conference cal...
Alligator Bioscience Names CFO Johan Giléus as CEO Amid Strategic Refocus on HLX22
Alligator Bioscience has appointed its current Chief Financial Officer, Johan Giléus, as Chief Executive Officer effective 1 January 2027, succeeding Søren Bregenholt, who will remain in the role until the end of 2026 to ensure a smooth handover. Gil...
Alligator Bioscience Restructures Fenja Loan With Directed Warrant Issue
Alligator Bioscience has issued 187,795,097 warrants to Fenja Capital as part of a renegotiated loan arrangement linked to its recently completed rights issue. The new 2026/2031 warrants, replacing an earlier 2025/2030 series, correspond to about 5 p...
Alligator Bioscience’s Rights Issue Heavily Reliant on Guarantees, Triggers Major Dilution
Alligator Bioscience has reported the final outcome of its rights issue of units, in which only about 17.1 percent of the maximum 3.14 billion units were subscribed by investors, with the remainder largely covered by guarantee commitments. Each unit...
Alligator Bioscience’s Rights Issue Undersubscribed, Underwriters Step In
Alligator Bioscience AB has reported the preliminary outcome of its rights issue of units, launched in July 2026, with subscriptions totaling about 17.1 percent through exercise of unit rights and 16.7 percent without rights. This level of demand mea...
Alligator Bioscience Launches SEK 125.6 Million Rights Issue to Refocus Oncology Pipeline
Alligator Bioscience has published a prospectus for a rights issue of up to 3,140,534,240 units, each comprising two shares and two series of warrants, at a subscription price of SEK 0.04 per unit. The offer, running from 4 to 18 September 2026, coul...
Alligator Bioscience Restructures Capital and Launches Major Rights Issue
Alligator Bioscience’s extraordinary general meeting approved multiple changes to its capital structure, including amendments to the Articles of Association and significant reductions of share capital to cover losses and reallocate funds to unrestric...
Alligator Bioscience exits mitazalimab development to refocus on HLX22 royalties and recapitalisation
Alligator Bioscience reported a weak second quarter with no significant operational events, continuing to post operating losses and declining cash, while progressing investigator-led studies and data presentations for mitazalimab and highlighting enc...
Alligator Bioscience Schedules August Earnings Call Amid Strategic Refocus
Alligator Bioscience will publish its interim report for the April–June 2026 period related to its HER2-targeting activities on 26 August 2026. On the same day, the company will host an earnings webinar and conference call in English, led by CEO Søre...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
